Biosketch / Results /
Daniel C. Fisher, M.D.
Associate Professor; Dir Nuclear Cardiology at BVDepartment of Medicine (Cardio Div)
NYU EKG Associates
NYU Cardiac Exercise / Stress Lab
NYU Cardiac Rehab Associates
Clinical Addresses
530 FIRST AVENUESUITE 4G
NEW YORK, NY 10016
Hours: Mon. 1 - 3; Thu. 2 - 4
Handicap Access: yes
Phone: 212-263-7229
Fax: 212-263-8630
Medical Specialties
Cardiology, Internal MedicineMedical Expertise
General Cardiology, Acute Myocardial Infarction, Arteriosclerosis, Lipid Metabolism, Radionuclide Imaging Cardilogy, Valvular DiseaseInsurance
AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO, AFFINITY, Beech St PPO, Cigna HMO/POS, Cigna PPO, EBCBS CHLD HLTH, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS POS, EBCBS PPO, FIDELIS CHLD HLTH, FIDELIS FAM HLTH, FIDELIS MEDICARE, Fidelis Medicaid, GHI CBP, GREATWEST PPO, HEALTHPLUS CHLD HLTH, HEALTHPLUS FAM HLTH, HIP ACCESS I, HIP ACCESS II, HIP CHLD HLTH, HIP EPO/PPO, HIP HMO, HIP MEDICARE, HIP POS, HealthPlus Medicaid, LOCAL 1199 PPO, MAGNACARE PPO, METROPLUS CHLD HLTH, METROPLUS FAM HLTH, MULTIPLAN/PHCS PPO, MetroPlus Medicaid, NYS EMPIRE PLAN, OXFORD FREEDOM, Oxford Medicare, UHC EPO, UHC HMO, UHC POS, UHC PPO, UHC TOP TIER, UPN EliteInsurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.
Board Certification
2006 — Internal Medicine2008 — Cardiovascular Disease (Internal Med)
Education
1992 — Medical College of Pennsylvania, Medical Education1992-1995 — Mount Sinai Hospital (Internal Medicine), Residency Training
1995-1998 — NYU Medical Center (Cardiology), Clinical Fellowships
All data from NYU Health Sciences Library Faculty Bibliography — -
Contact:
http://hsl.med.nyu.edu/faculty-bibliography-search#about
Clinical role of the Duke Activity Status Index in the selection of the optimal type of stress myocardial perfusion imaging study in patients with known or suspected ischemic heart disease
Phillips, Lawrence; Wang, Jing Wa; Pfeffer, Brad; Gianos, Eugenia; Fisher, Daniel; Shaw, Leslee J; Mieres, Jennifer H
2011 Dec;18(6):1015-1020, Journal of nuclear cardiology
BACKGROUND: Exercise treadmill stress myocardial perfusion imaging (MPI) with single photon emission computed tomography is commonly used to evaluate the extent and severity of inducible ischemia as well as to risk stratify patients with suspected and known coronary artery disease (CAD). Failure to reach adequate stress, defined as not attaining age-appropriate metabolic equivalents (METs), can underestimate the extent and severity of ischemic heart disease, resulting in false negative results. This study evaluates the efficacy of the Duke Activity Status Index (DASI), a simple self-administered 12-item questionnaire, as a predictor of METs achieved by treadmill stress testing. METHODS: The DASI was prospectively administered to 200 randomly selected men and women referred to the nuclear cardiology laboratory at New York University Langone Medical Center for stress MPI. Each patient was asked to complete the 12-item DASI questionnaire independently. 136 patients underwent treadmill exercise with MPI and 64 had pharmacologic stress with MPI. The association between exercise capacity in METs as estimated by the DASI questionnaire and performance on the Bruce treadmill protocol in METS was compared using chi-square statistics. RESULTS: Over 70% of those patients whose DASI score predicted the ability to perform <10 METs were unable to exercise beyond stage 2 of the Bruce protocol (7 METs). For those whose DASI score predicted ability to perform >12.5 METs, over 80% of patients reached >stage 2 of the Bruce protocol with 40% reaching beyond stage 3 (10 METs). When patient age was incorporated into the calculation, a more linear relationship was observed between predicted and obtained METs. CONCLUSION: The DASI is a simple self-administered questionnaire which is a useful pretest tool to determine a patient's ability to achieve appropriate METs. In the nuclear cardiology laboratory, the DASI has the potential to guide selection of exercise treadmill vs pharmacologic stress and ultimately improve laboratory efficiency
—
id: 141968,
year: 2011,
vol: 18,
page: 1015,
stat: Journal Article,
Transient apical ballooning syndrome precipitated by dobutamine stress testing
Skolnick, Adam H; Michelin, Krista; Nayar, Ambika; Fisher, Daniel; Kronzon, Itzhak
2009 Apr 7;150(7):501-502, Annals of internal medicine
—
id: 100049,
year: 2009,
vol: 150,
page: 501,
stat: Journal Article,
Reversible cardiomyopathy due to hyperthyroidism
Fisher DC; Fisher NDL
2000 ;21(8):427-432, Cardiovascular reviews & reports
The initial manifestations of hyperthyroidism frequently involve the cardiovascular system, and elevated thyroid hormone levels can produce a clinical scenario similar to a hyperadrenergic state. While much is known about the effects of thyroid hormone at the molecular level, the reasons why hyperthyroid patients develop atrial fibrillation or reversible cardiomyopathy remain elusive. In addition, recommendations for anticoagulation and appropriate treatment of associated heart failure vary. Using an illustrative case report, the authors discuss the effect of thyroid hormone on the heart, addressing clinical manifestations, pathophysiology, and controversial management issues. They conclude that the diagnosis of hyperthyroidism should be considered in patients with atrial fibrillation and that correct diagnosis is essential to successful management of the consequent cardiovascular manifestations. Hyperthyroidism can present with a broad range of signs and symptoms and frequently involves the cardiovascular system. Although much is known about the effects of thyroid hormone on a molecular and physiologic basis, the possible causal role of hyperthyroidism in atrial fibrillation and reversible cardiomyopathy remains poorly understood. In addition, there are varying approaches to anticoagulation and the treatment of heart failure associated with hyperthyroidism. (c) 2000 by Cardiovascular Reviews and Reports, Inc
—
id: 16056,
year: 2000,
vol: 21,
page: 427,
stat: Journal Article,
Large gradient across a partially ligated left atrial appendage
Fisher DC; Tunick PA; Kronzon I
1998 Dec;11(12):1163-1165, Journal of the American Society of Echocardiography
The left atrial appendage is frequently ligated during mitral valve surgery to decrease the future risk of embolic events. The postoperative detection of a partially occluded left atrial appendage has previously been reported with the use of transesophageal echocardiography. We describe an unusual case in which Doppler echocardiography demonstrated a remarkably high-velocity jet emanating from a partially ligated left atrial appendage
—
id: 7563,
year: 1998,
vol: 11,
page: 1163,
stat: Journal Article,
The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study
Fisher DC; Fisher EA; Budd JH; Rosen SE; Goldman ME
1995 Jun;107(6):1504-1509, Chest
STUDY OBJECTIVE: Patent foramen ovale (PFO) is present in 10 to 35% of people and has been reported to be an important risk factor for cardioembolic cerebrovascular accidents (CVAs) and transient ischemic attacks (TIAs), especially in younger patients. While contrast transthoracic echocardiography has been used to detect PFO, contrast transesophageal echocardiography (TEE) has a greater sensitivity. Prior studies reported the incidence of PFO in patients presenting with a CVA or TIA. DESIGN: To determine the incidence of PFO in a more general population, we reviewed 1,000 consecutive TEEs performed with contrast and color Doppler for the presence of PFO and other cardioembolic risk factors, including atrial septal aneurysm (ASA), aortic plaque, atrial fibrillation (AFib), and atrial thrombi. While imaging with monoplane or biplane TEE, multiple injections of agitated saline solution were injected during cough or Valsalva maneuver to detect flow through a PFO. PATIENTS: There were 482 male and 518 female patients with mean age of 60 +/- 17 years (range 11 to 93 years). RESULTS: Patent foramen ovale was found in 9.2% of all patients and, though seen in all age groups divided by decade, the incidence in patients aged 40 to 49 years was greater than those aged 70 to 79 years (12.96% vs 6.15%, p = 0.03). Contrast TEE had a much higher detection rate than color Doppler alone. Importantly, there was no greater incidence of PFO in patients with CVA vs those without CVA, or in male vs female patients. Also, there was a very strong correlation between the presence of ASA and PFO (p < .001). CONCLUSION: Thus, PFO detected by TEE, frequently seen with ASA, is seen in all age groups and does not in itself present a risk factor for CVA. The association of PFO with peripheral thrombosis and CVA needs further study
—
id: 22866,
year: 1995,
vol: 107,
page: 1504,
stat: Journal Article,


